HEALTHSTREAM INC (HSTM)
Sector: Health Care
2026 Annual Meeting Analysis
HEALTHSTREAM INC · Meeting: May 28, 2026
Directors FOR
1
Directors AGAINST
2
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Against Analysis
Mr. McLaren has served as a director since 1990, meaning his tenure fully overlaps the period of stock underperformance. HealthStream's shares have lost 24.1% over three years while the healthcare sector ETF (XLV) gained 15.7%, a gap of nearly 40 percentage points — well above the 30-point threshold that triggers a no vote when a company's stock has declined in absolute terms. The five-year return of -8.4% compared to XLV's long-term gains does not clear the bar for the mitigant that would otherwise downgrade this to a FOR vote, so an AGAINST vote is warranted.
Ms. Rebrovick has served as a director since 2001, so her tenure fully covers the underperformance period. HealthStream's stock has fallen 24.1% over the past three years while the healthcare sector ETF (XLV) rose 15.7%, a gap of roughly 40 percentage points that exceeds the 30-point policy threshold applicable when the stock has had a negative absolute return. The five-year track record (-8.4% for HSTM) also shows persistent underperformance relative to the sector benchmark, so the five-year mitigant that would convert this to a FOR vote does not apply, and an AGAINST vote is warranted.
For Analysis
Dr. Jahangir joined the board in 2023, which is within 24 months of the meeting date, so he is exempt from the stock performance trigger under policy; his medical leadership background at Vanderbilt University Medical Center is clearly relevant to HealthStream's healthcare-focused business.
Of the three Class II director nominees, Dr. Jahangir is exempt from the stock performance trigger because he joined the board in 2023 (within the 24-month exemption window) and receives a FOR vote. Mr. McLaren and Ms. Rebrovick, both long-tenured directors since 1990 and 2001 respectively, receive AGAINST votes because HealthStream's stock has significantly underperformed the healthcare sector ETF (XLV) over three years (-39.8 percentage points below XLV, exceeding the 30-point trigger threshold), and the five-year record does not support the mitigant that would soften the vote.
Say on Pay
✓ FORCEO
Robert A. Frist, Jr.
Total Comp
$868,037
Prior Support
94%%
The CEO's total reported compensation of $868,037 is modest for the chief executive of a $590 million healthcare technology company, and prior shareholder support for the pay program was very strong at approximately 94% in 2025, well above the 70% threshold that would require a response. The pay structure includes a mix of base salary, a cash bonus tied to adjusted EBITDA performance (which came in at 97.6% of target, reflecting genuine pay-for-performance linkage), time-based stock awards, and performance-based stock awards that fully vested only because the company met its adjusted EBITDA target — all of which represent legitimate variable compensation tied to measurable outcomes. While the company's stock has underperformed the sector over three years, the CEO's total pay level is low enough relative to benchmark expectations for this role and market cap that no pay level or pay-for-performance concern rises to the level of triggering a no vote.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$880,000
Non-Audit Fees
$0
Ernst & Young LLP charged $880,000 in audit fees for 2025 with zero non-audit fees of any kind — meaning the non-audit fee ratio is 0%, well below the 50% threshold that would raise independence concerns. Auditor tenure is not disclosed in the proxy, so the tenure trigger does not fire under policy. No material financial restatements are disclosed, and EY is a Big 4 firm fully appropriate for a company of HealthStream's size and complexity.
Overall Assessment
HealthStream's 2026 annual meeting presents three proposals: a director election where two of three nominees (McLaren and Rebrovick) receive AGAINST votes due to significant stock underperformance versus the XLV healthcare ETF during their long tenures, while the third nominee (Jahangir) is exempt as a recent joiner; auditor ratification for Ernst & Young earns a FOR vote given a clean fee structure with no non-audit fees; and the Say on Pay advisory vote also receives a FOR given modest CEO pay, strong prior shareholder support of 94%, and incentive awards genuinely tied to measurable financial performance targets.